Medica Pharmaceutical Industries LI Pharmaceutical Import Profile — Yemen (DGFT 2022–2026)

Name: Medica Pharmaceutical Industries LI Pharmaceutical Import Records from India — 2 Products, $370.2K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Medica Pharmaceutical Industries LI — Pharmaceutical Importer Profile (2026) | 2 Products, $370.2K Trade | TransData Nexus

Medica Pharmaceutical Industries LI

Pharmaceutical Importer · Yemen · Advanced Antibiotics Focus · $370.2K Total Trade · DGFT Verified

Medica Pharmaceutical Industries LI is a pharmaceutical importer based in Yemen with a total trade value of $370.2K across 2 products in 2 therapeutic categories. Based on 8 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Medica Pharmaceutical Industries LI sources from 1 verified Indian supplier, with Cipla Limited accounting for 100.0% of imports.

Medica Pharmaceutical Industries LI — Import Portfolio & Supplier Network

Medica Pharmaceutical Industries LI import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Medica Pharmaceutical Industries LI?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$1.2M	76	100.0%

Medica Pharmaceutical Industries LI sources from 1 verified Indian supplier across 41 distinct formulations. The sourcing is highly concentrated — Cipla Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Medica Pharmaceutical Industries LI Import?

Formulation	Value	Ships
Lomac 20 capsules (omeprazole 20 MG) inv.qty.16380 Pack 30x10's=4914000	$170.1K	9
Lomac 20 capsules (omeprazole 20 MG) inv.qty.16400 Pack 30x10's=4920000	$113.6K	6
Lomac 20 capsules (omeprazole 20 MG) inv.qty. 16396 Pack 30 x 10's =4918800	$56.8K	3
Lomac 20 capsules (omeprazole 20 MG) inv.qty.16392 Pack 30x10's=4917600	$56.8K	3
Lomac 20 capsules (omeprazole 20 MG) inv.qty.16400pack 30x10's=4920000	$56.8K	3
Lomac 20 capsules (omeprazole 20 MG) inv.qty.16375 Pack 30x10's=4912500	$56.7K	3
Lomac 20 capsules (omeprazole 20 MG) inv.qty.16360 Pack 30x10's=4908000	$56.6K	3
Cipazol forte tablets (secnidazole1000mg) (inv.qty. 48617 Pack 10x2's=972340 nos)	$50.0K	1
Cipazol forte tablets (secnidazole1000mg) (inv.qty. 48528 Pack 10x2's=970560 nos)	$50.0K	1
Cipazol forte tablets (secnidazole1000mg) (inv .qty. 41832 Pack 10x 12's=836640 nos )	$50.0K	1
Forcan 150 capsules (fluconazole 150MG) (inv.qty. 4751 Pack 50x1's=237550 nos)	$50.0K	1
Cipazol forte tablets (secnidazole1000mg) (inv.qty. 48965 Pack 10 x2's =979300 nos )	$50.0K	1
Alsin-100 tablets (acetyl salicylic acid 100MG) ( inv. qty. 14687 Pack 10x30's= 4406100 nos )	$43.6K	1
Alsin-100 tablets (acetyl salicylic acid 100MG) ( inv. qty. 14532 Pack 10x30's= 4359600 nos )	$43.2K	1
Alsin-100 tablets (acetyl salicylic acid 100MG) ( inv. qty. 14616 Pack 10x30's= 4384800 nos )	$41.9K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Secnidazole	Advanced Antibiotics	$200.0K	4	0.7%	4
2	Salicylic	Combination Drugs	$170.2K	4	1.0%	17

Medica Pharmaceutical Industries LI imports 2 pharmaceutical products across 2 categories into Yemen totaling $370.2K.

Medica Pharmaceutical Industries LI — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Medica Pharmaceutical Industries Limited is a pharmaceutical importer based in Yemen, specializing in the procurement of finished pharmaceutical formulations. Established with a vision to enhance Yemen's self-reliance in medicine production, the company operates from its headquarters in the Bani Matar area of Sana'a. The facility, covering 36,000 square meters, was completed in 2014 and is designed to meet internationally recognized quality standards, with provisions for future expansion.

As a key player in Yemen's pharmaceutical distribution network, Medica Pharmaceutical Industries Limited focuses on importing high-quality medicines to meet the evolving healthcare needs of the Yemeni population. The company's strategic location and state-of-the-art facilities underscore its commitment to delivering safe and effective pharmaceutical products.

2Distribution Network

Medica Pharmaceutical Industries Limited's distribution network is centered around its modern manufacturing facility in Sana'a, Yemen. The company has established a robust logistics system to ensure efficient distribution of pharmaceutical products across Yemen's major cities. While specific warehouse locations and logistics capabilities are not publicly detailed, the company's infrastructure is designed to support nationwide distribution, ensuring timely delivery of medicines to meet the country's healthcare demands.

3Industry Role

In Yemen's pharmaceutical supply chain, Medica Pharmaceutical Industries Limited functions primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from international suppliers, the company plays a crucial role in enhancing the availability of essential medicines within the country. This position enables Medica to address the diverse healthcare needs of the Yemeni population effectively.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Medica Pharmaceutical Industries LI

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Medica Pharmaceutical Industries Limited demonstrates a high degree of sourcing concentration, with all its pharmaceutical imports originating from a single supplier: Cipla Limited. This exclusive sourcing strategy indicates a strategic partnership aimed at ensuring consistent quality and supply. The company's total import value from India amounts to $370,000 USD, encompassing eight shipments and 41 unique formulations. The top five products imported include Secnidazole ($200,000, Rank #4, 0.7% share) and Salicylic ($170,000, Rank #17, 1.0% share). The primary therapeutic categories are Advanced Antibiotics (54.0%) and Combination Drugs (46.0%).

This sourcing concentration suggests a deliberate strategy to maintain supply chain stability and product quality. However, reliance on a single supplier may expose the company to risks associated with supply disruptions or changes in supplier terms. The absence of alternative suppliers in the data indicates a potential area for diversification to mitigate such risks.

2Supply Chain Resilience

Medica Pharmaceutical Industries Limited's supply chain resilience is closely tied to its exclusive relationship with Cipla Limited. The company's import data reveals a consistent pattern of shipments from this sole supplier, indicating a stable and reliable supply chain. However, the lack of backup suppliers introduces vulnerability to potential disruptions. The company's focus on importing finished pharmaceutical formulations, as opposed to raw APIs or bulk drugs, suggests a streamlined supply chain designed for efficiency. Ensuring that Cipla Limited adheres to international regulatory standards and maintains robust quality control measures is essential for sustaining the integrity of Medica's supply chain.

Importing Pharmaceuticals into Yemen — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Yemen

1Regulatory Authority & Framework

In Yemen, the primary regulatory authority overseeing pharmaceutical imports is the Ministry of Public Health and Population. The ministry is responsible for ensuring that all imported pharmaceutical products meet the country's health and safety standards. Key legislation governing pharmaceutical imports includes the Customs Law No. 14 of 1990 and its amendments, which outline the procedures and requirements for importing goods into Yemen. Additionally, Law No. 5 of 2020 exempts inputs for pharmaceutical production from customs duties, aiming to support the local pharmaceutical industry.

The marketing authorization pathway for Indian generics involves obtaining approval from the Ministry of Public Health and Population. This process includes submitting a Certificate of Pharmaceutical Products (COPP) issued by the competent authority in the country of origin, such as the U.S. FDA or another recognized regulatory body. The COPP must be legalized to confirm its authenticity for use in Yemen.

2Import Licensing & GMP

Import licensing requirements in Yemen stipulate that all pharmaceutical products must be registered with the Ministry of Public Health and Population before importation. This registration ensures that imported medicines meet the necessary quality and safety standards. Good Manufacturing Practice (GMP) certification is a critical component of the registration process. Yemen recognizes GMP certificates from reputable authorities, including the European Union (EU GMP), World Health Organization (WHO GMP), and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certifications from these recognized bodies to facilitate the importation process.

Medica Pharmaceutical Industries LI — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Medica Pharmaceutical Industries Limited's focus on importing advanced antibiotics and combination drugs aligns with the therapeutic needs of the Yemeni population. The high import values of Secnidazole and Salicylic indicate a significant demand for these medications. The company's strategy to import these specific therapeutic areas suggests a response to prevalent health issues in Yemen, such as infectious diseases and conditions requiring combination therapies. By concentrating on these categories, Medica aims to address critical healthcare challenges effectively.

2Sourcing Profile

Medica Pharmaceutical Industries Limited's sourcing strategy centers on importing generic drugs, primarily in the form of finished pharmaceutical formulations. The company's exclusive partnership with Cipla Limited reflects a preference for established suppliers known for their quality and reliability. This approach ensures a consistent supply of essential medicines, aligning with Medica's commitment to enhancing healthcare in Yemen.

3Market Positioning

Based on its product mix, Medica Pharmaceutical Industries Limited serves a broad segment of the Yemeni market, including retail pharmacies, hospitals, and government tenders. The company's focus on essential medicines positions it as a key supplier in the country's healthcare system, catering to various healthcare providers and institutions.

Seller's Guide — How to Become a Supplier to Medica Pharmaceutical Industries LI

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Yemeni market by partnering with Medica Pharmaceutical Industries Limited. The company's exclusive sourcing from Cipla Limited indicates a potential openness to diversifying its supplier base. New suppliers can offer competitive pricing, innovative products, or specialized formulations to meet the evolving needs of the Yemeni market. However, establishing a partnership would require compliance with Yemen's regulatory requirements, including obtaining the necessary import licenses and GMP certifications.

2Requirements & Qualifications

Indian exporters seeking to supply Medica Pharmaceutical Industries Limited and the Yemeni market must ensure that their products are registered with the Ministry of Public Health and Population in Yemen. This registration necessitates providing a Certificate of Pharmaceutical Products (COPP) issued by a recognized authority, such as the U.S. FDA. The COPP must be legalized to confirm its authenticity for use in Yemen. Additionally, exporters must ensure that their manufacturing facilities hold valid GMP certifications from recognized bodies, including EU GMP, WHO GMP, or PIC/S. Compliance with these standards is essential for facilitating the importation process and ensuring product acceptance in the Yemeni market.

Frequently Asked Questions — Medica Pharmaceutical Industries LI

What products does Medica Pharmaceutical Industries LI import from India?

Medica Pharmaceutical Industries LI imports 2 pharmaceutical products across 2 categories. Top imports: Secnidazole ($200.0K), Salicylic ($170.2K).

Who supplies pharmaceuticals to Medica Pharmaceutical Industries LI from India?

Medica Pharmaceutical Industries LI sources from 1 verified Indian suppliers. The primary supplier is Cipla Limited (100.0% of imports, $1.2M).

What is Medica Pharmaceutical Industries LI's total pharmaceutical import value?

Medica Pharmaceutical Industries LI's total pharmaceutical import value from India is $370.2K, based on 8 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Medica Pharmaceutical Industries LI focus on?

Medica Pharmaceutical Industries LI imports across 2 categories. The largest: Advanced Antibiotics (54.0%), Combination Drugs (46.0%).

Get Full Medica Pharmaceutical Industries LI Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.